Nucleus Labs announcement

Nucleus Origin

A family of the most predictive genetic models ever built.

token

State-of-the-art prediction

Origin surpasses all published accuracy benchmarks for predicting age-related conditions like Alzheimer’s, cancers, and diabetes from embryonic DNA.

fiber_smart_record

Open-weight

Origin’s model weights are publicly available. We welcome the entire research community to explore, validate, and build upon our research.

published_with_changes

Rigorously validated

The models have been trained and validated on millions of people across diverse ancestries.

Liability R² by disease

Origin
Thompson
Mars

Liability R2

0.3

0.2

0.1

0

Alzheimer's disease
Breast cancer
CAD
Endometriosis
Hypertension
Prostate cancer
Rheumatoid arthritis
Type 1 diabetes
Type 2 diabetes

Introducing Origin

We've had a breakthrough in applying AI to genetic analysis.

Origin is a family of nine genetic optimization models that predict human longevity from an embryo’s DNA more accurately than any genetic model to date.

Trained and validated on data from millions of individuals, Origin sets new accuracy benchmarks for predicting age-related conditions such as heart disease and cancers across diverse ancestries.

Developed by Nucleus Labs, our research arm, Origin reflects a commitment to both scientific rigor and transparency. Origin’s full model weights will be publicly available, allowing patients, providers, and researchers to see how the models work, evaluate their performance, and build upon them.

Specifically, the Origin models will be hosted in the Genetic Optimization Hub, a public resource for all companies, laboratories, and academics to publish and compare model accuracy. Each model entry will include information on training and validation data, uncertainty ranges, and performance across ancestries to support clarity and reproducibility. 

Until now, Nucleus’ models — like others in the industry — were considered proprietary, making it difficult for providers, parents, and researchers to understand and evaluate them. We’re changing that because we believe the future of genomics should be built in public.

With the open-weighting of Origin, patients can see how genetics can ensure a long and healthy life for themselves and their child. Providers can recognize that genetic optimization is ready for clinical integration. And regulators can see genetic optimization for what it truly is: the ultimate tool for preventative medicine.

For Nucleus, science is only complete when it helps a family. Nucleus is proud that Origin is already in use with our IVF+ partners, reaching patients through leading IVF practitioners in Los Angeles, New York, and Mexico City. All existing Nucleus Family and Health patients will also receive these updates, helping thousands more families around the world.  

Together with our IVF and reproductive medicine partners, we’re making genetic innovation available to families everywhere.

To the patients who place their trust in us—thank you. Whether our DNA kits or IVF+, we’re honored to support you in building generational health.

We've had a breakthrough in applying AI to genetic analysis.

Origin is a family of nine genetic optimization models that predict human longevity from an embryo’s DNA more accurately than any genetic model to date.

Trained and validated on data from millions of individuals, Origin sets new accuracy benchmarks for predicting age-related conditions such as heart disease and cancers across diverse ancestries.

Developed by Nucleus Labs, our research arm, Origin reflects a commitment to both scientific rigor and transparency. Origin’s full model weights will be publicly available, allowing patients, providers, and researchers to see how the models work, evaluate their performance, and build upon them.

Specifically, the Origin models will be hosted in the Genetic Optimization Hub, a public resource for all companies, laboratories, and academics to publish and compare model accuracy. Each model entry will include information on training and validation data, uncertainty ranges, and performance across ancestries to support clarity and reproducibility. 

Until now, Nucleus’ models — like others in the industry — were considered proprietary, making it difficult for providers, parents, and researchers to understand and evaluate them. We’re changing that because we believe the future of genomics should be built in public.

With the open-weighting of Origin, patients can see how genetics can ensure a long and healthy life for themselves and their child. Providers can recognize that genetic optimization is ready for clinical integration. And regulators can see genetic optimization for what it truly is: the ultimate tool for preventative medicine.

For Nucleus, science is only complete when it helps a family. Nucleus is proud that Origin is already in use with our IVF+ partners, reaching patients through leading IVF practitioners in Los Angeles, New York, and Mexico City. All existing Nucleus Family and Health patients will also receive these updates, helping thousands more families around the world.  

Together with our IVF and reproductive medicine partners, we’re making genetic innovation available to families everywhere.

To the patients who place their trust in us—thank you. Whether our DNA kits or IVF+, we’re honored to support you in building generational health.

Founder & CEO

Founder & CEO

Founder & CEO

Nucleus Genomics, Inc.

Nucleus Genomics, Inc.

Nucleus Genomics, Inc.

Meet the scientists and doctors
behind Origin.

Lasse Folkersen, Ph.D.

Chief Scientific Officer at Nucleus, author of 100+ peer-reviewed publications, and pioneer of polygenic risk scores.

Chief Scientific Officer at Nucleus, author of 100+ peer-reviewed publications, and pioneer of polygenic risk scores.

Chief Scientific Officer at Nucleus, author of 100+ peer-reviewed publications, and pioneer of polygenic risk scores.

Nathan Treff, Ph.D., HCLD

Chief Clinical Officer at Nucleus, author of 100+ peer-reviewed publications, and creator of advanced embryo genetic diagnostics.

Chief Clinical Officer at Nucleus, author of 100+ peer-reviewed publications, and creator of advanced embryo genetic diagnostics.

Chief Clinical Officer at Nucleus, author of 100+ peer-reviewed publications, and creator of advanced embryo genetic diagnostics.

Ellen H. Goldstein, MD

Double board-certified OB-GYN and Reproductive Endocrinologist. Dr. Goldstein co-founded Beverly Hills Fertility, one of America's leading fertility clinics.

Double board-certified OB-GYN and Reproductive Endocrinologist. Dr. Goldstein co-founded Beverly Hills Fertility, one of America's leading fertility clinics.

Double board-certified OB-GYN and Reproductive Endocrinologist. Dr. Goldstein co-founded Beverly Hills Fertility, one of America's leading fertility clinics.

Enrique Cervantes, MD

Double board-certified OB-GYN and Reproductive Endocrinologist. Dr. Cervantes co-founded C de la F, Latin America’s top fertility clinic.

Double board-certified OB-GYN and Reproductive Endocrinologist. Dr. Cervantes co-founded C de la F, Latin America’s top fertility clinic.

Double board-certified OB-GYN and Reproductive Endocrinologist. Dr. Cervantes co-founded C de la F, Latin America’s top fertility clinic.

Simon Fishel, Ph.D.

IVF pioneer who helped create the world's first IVF baby. Author of 200+ peer-reviewed publications and founder of numerous IVF clinics around the world.

IVF pioneer who helped create the world's first IVF baby. Author of 200+ peer-reviewed publications and founder of numerous IVF clinics around the world.

IVF pioneer who helped create the world's first IVF baby. Author of 200+ peer-reviewed publications and founder of numerous IVF clinics around the world.

Jerry Lanchbury, Ph.D

Former Chief Scientific Officer at Myriad Genetics and current member of the Nucleus Scientific Advisory Board.

Former Chief Scientific Officer at Myriad Genetics and current member of the Nucleus Scientific Advisory Board.

Former Chief Scientific Officer at Myriad Genetics and current member of the Nucleus Scientific Advisory Board.

Margit Burmeister, Ph.D.

Professor of Human Genetics and Associate Chair of Computational Medicine at UMich Medical School. Author of 300+ peer-reviewed publications.

Professor of Human Genetics and Associate Chair of Computational Medicine at UMich Medical School. Author of 300+ peer-reviewed publications.

Professor of Human Genetics and Associate Chair of Computational Medicine at UMich Medical School. Author of 300+ peer-reviewed publications.

Dianne Keen-Kim, Ph.D., FACMG, HCLD

Adjunct Clinical Professor of Pathology at Stanford Medical School. PhD in Biological Sciences from the MIT.

Adjunct Clinical Professor of Pathology at Stanford Medical School. PhD in Biological Sciences from the MIT.

Adjunct Clinical Professor of Pathology at Stanford Medical School. PhD in Biological Sciences from the MIT.

Share the news on:

Share on:

Share on:

sun in the sky during daytime

Genetic Optimization Hub

A public hub for companies, labs and researchers to open-weight and share the accuracy of their models.

sun in the sky during daytime

Genetic Optimization Hub

A public hub for companies, labs and researchers to open-weight and share the accuracy of their models.

sun in the sky during daytime

Genetic Optimization Hub

A public hub for companies, labs and researchers to open-weight and share the accuracy of their models.